%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-01-16T14:24:24+05:30
2017-01-16T14:24:24+05:30
2017-01-16T14:24:24+05:30
Adobe InDesign CS6 (Macintosh)
uuid:b5f34825-9981-bf47-948f-cf80f19cc72d
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:C02E350118206811822ACB128E595E5F
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-01-16T14:24:24+05:30
xmp.iid:BA2E350118206811822ACB128E595E5F
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
38 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 564.9999 45.4294 Tm
(11)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
q
0 0 612 792 re
W n
BT
/T1_1 1 Tf
13 0 0 13 36 438.6647 Tm
(R)Tj
9.1 0 0 9.1 44.6709 438.6647 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
10 0 0 10 36 413.6647 Tm
( )Tj
EMC
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.288 Tw 1.8 0 Td
[(Salg)4.9(ado CD)59.8(, F)59.8(ar)-29.8(r BM, Calfee DP)160(. Community-acquired )]TJ
0 Tw 0 -1.2 TD
(methicillin-resistant )Tj
/T1_3 1 Tf
-0.02 Tw 8.229 0 Td
[(Staph)19.8(ylococcus )0.6(aur)36.9(eus)]TJ
/T1_2 1 Tf
[(: )0.5(a )0.6(meta-anal)24.9(ysis )]TJ
0.078 Tw -8.229 -1.2 Td
[(of pre)24.9(v)24.9(alence and risk f)-9.8(actors. Clinical infectious diseases: )]TJ
0.045 Tw T*
[(an of\036cial pub)19.8(lication of the Infectious Diseases )0.5(Society of )]TJ
0 Tw T*
(America. 2003;36\(2\):131\2269.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.17 Tw 1.8 0 Td
[(Huang )0.5(H, Fl)24.9(ynn NM, )0.5(King )0.5(JH, Monchaud )0.5(C, Morita )0.5(M, )]TJ
0.178 Tw T*
(Cohen SH. Comparisons of community-associated methi)Tj
0 Tw (-)Tj
T*
(cillin-resistant )Tj
/T1_3 1 Tf
0.14 Tw 6.112 0 Td
[(Staph)19.8(ylococcus )0.5(aur)36.8(eus )]TJ
/T1_2 1 Tf
9.665 0 Td
[(\(MRSA\) )0.5(and hospi)]TJ
0 Tw (-)Tj
0.091 Tw -15.777 -1.2 Td
[(tal-associated MSRA infections in Sacramento, Califor)-19.7(nia. )]TJ
0 Tw T*
[(Jour)-19.8(nal of clinical microbiolo)25(gy)85(. 2006;44\(7\):2423\2267.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.241 Tw 1.8 0 Td
[(Naimi )49.4(TS, LeDell KH, Como-Sabetti K, Borchardt SM, )]TJ
0.007 Tw T*
[(Bo)19.8(xr)-19.8(ud DJ)59.8(, Etienne J)59.8(, et al. Comparison of community- and )]TJ
0.166 Tw T*
(health care-associated methicillin-resistant)Tj
/T1_3 1 Tf
[( Staph)19.7(ylococcus )]TJ
0 Tw T*
[(aur)36.9(eu)]TJ
/T1_2 1 Tf
[(s infection. J)49.8(AMA. 2003;290\(22\):2976-84.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.157 Tw 1.8 0 Td
[(Da)34.9(vid MZ, Daum RS. Community-associated methicillin-)]TJ
0 Tw ( )Tj
T*
(resistant )Tj
/T1_3 1 Tf
0.078 Tw 3.661 0 Td
[(Staph)19.8(ylococcus aur)36.9(eus)]TJ
/T1_2 1 Tf
[(: epidemiolo)25(gy and clinical )]TJ
0.027 Tw -3.661 -1.2 Td
[(consequences of an emer)17.9(ging epidemic. Clinical microbiol)]TJ
0 Tw (-)Tj
T*
[(o)24.9(gy re)24.9(vie)24.9(ws. 2010;23\(3\):616-87.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.212 Tw 1.8 0 Td
[(F)19.8(razee BW)149.9(, F)49.8(ee C, Lamber)-19.7(t L. Ho)39.8(w common is MRSA )]TJ
0.241 Tw T*
[(in )0.5(adult )0.6(septic )0.6(ar)-19.8(thritis? )55.6(Annals )0.5(of )0.6(emer)17.9(genc)14.9(y )0.5(medicine. )]TJ
0 Tw T*
(2009;54\(5\):695-700.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
26.4 51.55 Td
( )Tj
EMC
[(6)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.364 Tw 1.8 0 Td
[(Ross JJ)59.8(, Da)35(vidson L. Methicillin-resistant Staph)29.7(ylococ)]TJ
0 Tw (-)Tj
0.104 Tw T*
[(cus )0.6(aureus )0.5(septic )0.6(ar)-19.8(thritis: )0.6(an )0.5(emer)17.8(ging )0.5(clinical )0.6(syndrome. )]TJ
0 Tw T*
[(Rheumatolo)24.9(gy \(Oxford\). 2005;44\(9\):1197-8.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(7)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.305 Tw 1.8 0 Td
[(Sharf)24.9(f KA, Richards EP)159.9(, )49.7(T)79.9(o)39.7(wnes JM. Clinical manage)]TJ
0 Tw (-)Tj
0.382 Tw T*
[(ment of septic ar)-19.8(thritis. Cur)-29.8(rent rheumatolo)24.9(gy repor)-19.8(ts. )]TJ
0 Tw T*
(2013;15\(6\):332.)Tj
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(8)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.337 Tw 1.8 0 Td
[(Byr)-19.8(ne P)119.9(A, Hosein IK, Camilleri J)59.9(. Methicillin-resistant )]TJ
/T1_3 1 Tf
-0.01 Tw T*
[(Staph)19.8(ylococcus aur)36.9(eus)]TJ
/T1_2 1 Tf
[( septic ar)-19.7(thritis: ur)17.9(gent and emer)17.9(gent. )]TJ
0 Tw T*
[(Clinical rheumatolo)25(gy)84.9(. 1998;17\(5\):407-8.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.28 Tw /Span<>> BDC
-1.8 -1.2 Td
( )Tj
EMC
[(9)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.2 Tw 1.8 0 Td
[(Lodise )49.5(TP)159.9(, McKinnon PS, Swiderski L, Rybak MJ)59.8(. Out)]TJ
0 Tw (-)Tj
0.198 Tw T*
[(comes anal)25(ysis of dela)34.9(y)19.8(ed antibiotic treatment for hospi)]TJ
0 Tw (-)Tj
T*
(tal-acquired)Tj
/T1_3 1 Tf
0.384 Tw [( )0.5(Staph)19.8(ylococcus )0.6(aur)36.8(eus)]TJ
/T1_2 1 Tf
[( )0.5(bacteremia. )0.6(Clinical )]TJ
0.024 Tw T*
[(infectious diseases : an of\036cial pub)19.8(lication of the Infectious )]TJ
0 Tw T*
[(Diseases Society of )55.1(America. 2003;36\(11\):1418-23.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(10.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
-0.053 Tw 0.58 0 Td
[(K)24.9(essler CS, Kane K, De)24.9(v S, Smile)14.9(y JL. Inadequate postg)-19.8(rad)]TJ
0 Tw (-)Tj
0.094 Tw T*
(uate training of skin and soft tissue infections in an era of )Tj
0.15 Tw T*
(community-associated methicillin-resistant )Tj
/T1_3 1 Tf
0 Tw [(Staph)19.7(ylococcus )]TJ
T*
[(aur)36.9(eus)]TJ
/T1_2 1 Tf
0.053 Tw [(. Jour)-19.8(nal of in)39.8(v)14.9(estig)4.9(ati)24.9(v)14.9(e medicine : the of\036cial pub)]TJ
0 Tw (-)Tj
0.119 Tw T*
[(lication of the )55.1(American F)49.8(ederation for Clinical Research. )]TJ
0 Tw T*
(2013;61\(6\):1026-9.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(11.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.104 Tw 0.58 0 Td
[(V)128.9(onk J)59.9(, Shack)9.8(elford )50(TK, editors. )50(The Oxford handbook of )]TJ
0.246 Tw T*
[(comparati)25(v)14.9(e e)24.9(v)19.8(olutionar)-19.8(y psycholo)24.9(gy)85(. Ne)25(w )89.5(Y)160(ork: Oxford )]TJ
0 Tw T*
[(Uni)24.9(v)14.9(ersity Press; 2012.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(12.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.225 Tw 0.58 0 Td
[(Da)34.9(vid MZ, Cra)39.8(wford SE, Bo)45(yle-V)110.8(a)35(vra S, Hostetler MA, )]TJ
0.056 Tw T*
(Kim DC, Daum RS. Contrasting pediatric and adult methi)Tj
0 Tw (-)Tj
T*
(cillin-resistant )Tj
/T1_3 1 Tf
0.304 Tw 6.276 0 Td
[(Staph)19.8(ylococcus aur)36.9(eus)]TJ
/T1_2 1 Tf
[( isolates. Emer)17.9(ging )]TJ
0 Tw -6.276 -1.2 Td
(infectious diseases. 2006;12\(4\):631-7.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(13.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.017 Tw 0.58 0 Td
[(Charlebois ED)59.8(, Bangsber)17.9(g DR, Moss NJ)59.8(, Moore MR, Moss )]TJ
-0.012 Tw T*
[(AR, Chambers HF)129.9(, et al. P)39.8(opulation-based community pre)24.9(v)]TJ
0 Tw (-)Tj
0.038 Tw T*
(alence of methicillin-resistant)Tj
/T1_3 1 Tf
[( Staph)19.8(ylococcus aur)36.9(eus)]TJ
/T1_2 1 Tf
( in the )Tj
0.146 Tw T*
[(urban poor of San F)19.8(rancisco. Clinical infectious diseases: )]TJ
0.045 Tw T*
[(an of\036cial pub)19.8(lication of the Infectious Diseases )0.5(Society of )]TJ
0 Tw T*
(America. 2002;34\(4\):425-33.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(14.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.148 Tw 0.58 0 Td
[(Baggett HC, Hennessy )50.1(TW)149.9(, Leman R, Hamlin C, Br)-19.8(uden )]TJ
0.165 Tw T*
[(D)59.8(, Reasono)45(v)14.9(er )55.3(A, )0.5(et al. )55.3(An outbreak )0.5(of community-onset )]TJ
0 Tw T*
(methicillin-resistant )Tj
/T1_3 1 Tf
0.126 Tw 8.376 0 Td
[(Staph)19.8(ylococcus aur)36.9(eus)]TJ
/T1_2 1 Tf
( skin infections )Tj
0.09 Tw -8.376 -1.2 Td
[(in southw)34.9(ester)-19.7(n )55(Alaska. Infection control and hospital epi)]TJ
0 Tw (-)Tj
0.115 Tw T*
[(demiolo)24.9(gy : the of\036cial jour)-19.8(nal of the Society of Hospital )]TJ
0 Tw T*
[(Epidemiolo)24.9(gists of )55(America. 2003;24\(6\):397-402.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(15.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_2 1 Tf
0.087 Tw 0.58 0 Td
[(W)79.8(ang )29.8(WY)129(, Lee SY)129(, Chiueh )49.8(TS, Lu JJ)59.8(. Molecular and phe)]TJ
0 Tw (-)Tj
0.211 Tw T*
[(notypic characteristics of methicillin-resistant and v)25(anco)]TJ
0 Tw (-)Tj
T*
[(m)39.8(ycin-inter)-19.7(mediate )]TJ
/T1_3 1 Tf
0.34 Tw 8.401 0 Td
[(Staph)19.8(ylococcus )0.6(aur)36.8(eus)]TJ
/T1_2 1 Tf
[( )0.5(isolates )0.5(from )]TJ
0.098 Tw -8.401 -1.2 Td
[(patients with septic ar)-19.8(thritis. Jour)-19.7(nal of clinical microbiol)]TJ
0 Tw (-)Tj
T*
[(o)24.9(gy)85(. 2009;47\(11\):3617-23.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
( )Tj
ET
0 0 0 1 K
q 1 0 0 1 36 696.5 cm
0 0 m
258 0 l
S
Q
q 1 0 0 1 36 490.5 cm
0 0 m
258 0 l
S
Q
BT
/TT0 1 Tf
10 0 0 10 36 678 Tm
(Article citation:)Tj
10.5 0 0 10.5 108.7881 678 Tm
( )Tj
/TT1 1 Tf
[(Lim SY)128.7(, Panikkath D, Ratra )55.1(A, )]TJ
-6.932 -1.19 Td
(Panikkath R, Nugent K. Clinical characteristics and )Tj
0 -1.19 TD
(outcomes of community-acquired methicillin resistant )Tj
/TT2 1 Tf
0 -1.19 TD
(Staphylococcus aureus)Tj
/TT1 1 Tf
10.339 0 Td
[( septic arthritis. )18.1(The Southwest )]TJ
/C2_0 1 Tf
-10.339 -1.19 Td
<0035004800560053004C00550044005700520055005C0003004400510047000300260055004C0057004C00460044004F0003002600440055004800030026004B005500520051004C0046004F004800560003001500130014001A001E0018000B0014001A000C001D>Tj
/TT1 1 Tf
23.232 0 Td
( )Tj
-23.232 -1.19 Td
[(5-1)73.9(1.)]TJ
/TT0 1 Tf
10 0 0 10 36 603 Tm
(From:)Tj
10.5 0 0 10.5 64.3301 603 Tm
( )Tj
/TT1 1 Tf
[(Division of Rheumatology)72.3(, )55.5(Allergy and )]TJ
-2.698 -1.19 Td
[(Immunology)73.4(, Massachusetts General Hospital, Boston, )]TJ
/C2_0 1 Tf
0 -1.19 TD
<003000440056005600440046004B0058005600480057005700560003000B002F004C0050000C001E000300270048005300440055005700500048005100570003005200490003002C005100570048005500510044004F0003003000480047004C0046004C00510048000F0003>Tj
/TT1 1 Tf
0 -1.19 TD
[(T)111(exas )17.9(T)111(ech University Health Sciences Center)53.2(, )]TJ
0 -1.19 TD
[(Lubbock, )17.6(T)111(exas \(Panikkath, Ratra, Panikkath, Nugent\))]TJ
/TT0 1 Tf
10 0 0 10 36 540.5 Tm
(Submitted:)Tj
/TT1 1 Tf
10.5 0 0 10.5 88.2168 540.5 Tm
( 6/15/2016)Tj
/TT0 1 Tf
10 0 0 10 36 528 Tm
(Accepted:)Tj
/TT1 1 Tf
10.5 0 0 10.5 84.3447 528 Tm
[( 1)74.2(1/28/2016)]TJ
/TT0 1 Tf
10 0 0 10 36 515.5 Tm
(Reviewers:)Tj
/TT1 1 Tf
10.5 0 0 10.5 88.8076 515.5 Tm
( John Pixley MD, Richard Winn MD, )Tj
16.171 0 Td
( )Tj
-21.2 -1.19 Td
(George Brindley MD)Tj
ET
endstream
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 45.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(17\):5\226\
11)Tj
ET
endstream
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 36 59.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 36 731.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 742.5262 Tm
(Clinical Characteristics and Outcomes)Tj
/Span<>> BDC
( )Tj
EMC
63.443 0 Td
(Lim et al.)Tj
ET
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>stream
H\j0l/JkB`-bR[c"o?)*3:ձr{LSI
3|MxQr=k}sg;\p`1t
^CT1XlK_!Z6%7=BiGc:g:Bg]ZdO'dK,Ls,LX5y'cf>
hլ!u3X7]2<8hk@c^V̗'9|l(` j]
endstream
endobj
45 0 obj
<>stream
HlU TTGBdTi1(*kP0l*w4jDDMT،c#F.IF=s8'w__w߽A a1$B>{-uZriIc6RS=\ %Pb[0*߫lبӣOٟ_,h\u}t ^iAsG$9Lw QC>e2)19EkguhO*_Bo+)*ǶEvԺ& Z4TNBX +JLHAF@:쨹߸-@M5~#:ޔzf6v[lҺMv=;}ٻOn{ջO~?xaG|0rBƌq -'M"cbϘ4kvrʜԹƴy_p%Kӗ-lUX6k
ظ/7oٚmrrv뽲},.)-;tcOoO9{|Ņʪ/^+W]n߹{ᄅLG1a!4F(^}ENo{]
al
C;!0^LXWd?ciJsAo7'?~
ii0ߖvyeskjfԤ6rLM+SiiN]ZTaI ,?M"˰ϱ 2۰yxtlkV[VO؎Q)rP
7iB$*w\eC`*!u01Cv"H sFC>!"b,#<@
nR4Q3XSX1G4xƧyV߸gNH8`lE#sLcVw#ctB$!kyFWeh5c6g\1봵 k8c(zDVțZ=VjkXz"EPd͛9l(W@-#pi7zwS>oN:梒֊(1G
5Tۢ-|*y<ȁNQtR/̯<μ#z`0s%3Ur^Q(E/LRT%FkpmQlA"FlD01dRJ6oraU5=9;u VtIo#1 \F:sl۰̻̉̕|xI6K?ESky!DWD!rDta|we$+W06g5v^Ek`437>a/a%fq/ Qf=+b#GjEyQ0JIY s4tczF/YX[^Dg-`#V,Q(Jq⺸%:\ґ =d%e44Pe;F,͝|m͊U>;W &VL:G-:4p@~}ճGwn]}xwgGnW}vm۴vqvjղCs{;[feꃛ8Β[q糄$BXYk( M0ń ɐ-mmJIzI@f&3
q:1L`oѩwov}@q9UoFerKKrtt=ՑQEJQŌ&xF< 6ƀ_ˢzYx}G6)QvMfR $1,8#ĞmJ<2br!D#HSeX(gaByZ$7BҞxW#ovKR*Wqlܭ"yji.(Fec*F#AG!r,+/GژTymV]OTx%xꦕO$`GiDT
c)O"$ B'ST'=W۔ HQQ>i(::}EeMR&j.!sHaT,o CiV/xZ蝳iN981H:*n!'Mo=RԃRF=@Ce#Ȣrg{f{Xp$\|jU.DB4}q'K~AV%aX!Kah6AQv$gtuQ4KTX[kc{V+V|+;dzW04aԤ9b`4jp:#?N"2ְT89W9lsՆ7?]^O,9/q6λ݇7'OA'D\gz>ha bS-UVZwZusHބJC(^\h#_)܃4
rз](D^)